A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer

Citation
Y. Akiyama et al., A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer, JPN J CLIN, 31(10), 2001, pp. 482-487
Citations number
30
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
ISSN journal
0368-2811 → ACNP
Volume
31
Issue
10
Year of publication
2001
Pages
482 - 487
Database
ISI
SICI code
0368-2811(200110)31:10<482:ADESOP>2.0.ZU;2-7
Abstract
Background: The combination of paclitaxel (225 mg/m(2), 3-h infusion) and c arboplatin (area under the curve 6) is widely used for non-small cell lung cancer in the USA. In Japan, however, the recommended dose for single-use p aclitaxel in 3-h infusion is 210 mg/m(2) and the optimal dose of this agent in combination with carboplatin has not been established. This dose escala tion study was designed to determine the maximum tolerated dose of paclitax el in 3-h infusion plus carboplatin at a fixed dose of area under the curve 6 for Japanese patients with advanced, untreated non-small cell lung cance r. Methods: Between October 1999 and May 2000, 19 patients were enrolled and 1 8 of these patients were evaluable for toxicity. Chemotherapy consisted of carboplatin area under the curve 6 and an escalated dose of paclitaxel on d ay 1 every 3-4 weeks. The initial dose of paclitaxel was 175 mg/m(2) and wa s increased by 25 mg/m(2) at each dose level. Results: Neutropenia was the major toxicity observed, but was not dose rela ted. Febrile neutropenia was not observed. No grade 3 or more peripheral ne uropathy, myalgia or arthralgia was reported. The maximum tolerated dose wa s not determined even at the highest paclitaxel dose level (225 mg/m(2)) in this study. Partial responses were observed in six of the 19 patients (31. 6%). Conclusion: We conclude that paclitaxel at 225 mg/m(2) in 3-h infusion and carboplatin area under the curve 6 can safely be given to Japanese patients with non-small cell lung cancer.